Lupin is currently trading at Rs. 734.85, up by 5.75 points or 0.79% from its previous closing of Rs. 729.10 on the BSE.
The scrip opened at Rs. 735.00 and has touched a high and low of Rs. 738.50 and Rs. 731.75 respectively. So far 31159 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 759.20 and Rs. 726.00 respectively. The current market cap of the company is Rs. 33250.73 crore.
The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.
YL Biologics (YLB), a joint venture between Lupin's subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo Inc. in Japan, and Lupin (through its Japanese subsidiary, Kyowa Pharmaceutical Industry) have received an approval from Pharmaceutical and Medical Devices Agency (PMDA) to manufacture and sell their biosimilar Etanercept in Japan. The approval to treat moderate to severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis was received on March 26, 2019.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
